A Phase 2 interventional study of Umbralisib in Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia and Non Follicular Indolent Non-Hodgkin Lymphoma, sponsored by TG Therapeutics, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-23.
Sponsored by TG Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 674 studies in Lymphoma, B-Cell, Marginal Zone with a site in United States — 57 open to participants now, 95 under way, 6 of them phase 3. Lymphoma, B-Cell, Marginal Zone · United States.
Among the 674 studies in Lymphoma, B-Cell, Marginal Zone with a site in United States, this one is the 385th largest by enrollment of the 557 interventional ones that give a count, is one of 25 that started in 2017, is one of 224 in phase 2, and was the 553rd registered.
877 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 113 are open to participants now.
Browse Lymphoma, B-Cell, Marginal Zone studies →57 of the 674 studies in Lymphoma, B-Cell, Marginal Zone with a site in United States are open now. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
Paolo Caimi, MD · Sites in United States
Ages 18+
Taiho Oncology, Inc. · Sites in United States, Australia, France and 3 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, Canada and 9 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 93 Lymphoma, B-Cell, Marginal Zone studies recruiting now, 78 (84%) set no upper age limit and 7 (8%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
674 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 325 · Phase 2 306 · Phase 3 45 · Phase 4 1
First in 1988; this study’s year is marked. 25 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 40 across 683 interventional studies indexed under Lymphoma, B-Cell, Marginal Zone.
Median enrollment 36 across the 557 interventional studies, 55 across the 33 observational. Of the 539 that completed or were terminated, 182 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
113 of 674 have an industry lead sponsor. The 10 most frequent:
TG Therapeutics, Inc. is the lead sponsor of 40 studies on the registry; 9 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
TG Therapeutics, Inc. has 5 studies filed under Lymphoma, B-Cell, Marginal Zone — fewer than ten, so there is no comparison to draw.
25 of the studies in Lymphoma, B-Cell, Marginal Zone with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04799275Phase 3National Cancer Institute (NCI)Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | 2027-03-01 |
| NCT04212013Phase 3Memorial Sloan Kettering Cancer CenterA Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma | 2027-03-18 |
| NCT01479842Kami Maddocks, MDRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | 2026-12-01 |
| NCT06860880UNC Lineberger Comprehensive Cancer CenterCombating Cancer-Related Fatigue: A Personalized Supportive Care Program | 2026-12-31 |
| NCT05700149International Extranodal Lymphoma Study Group (IELSG)Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma | 2026-12-31 |
Add all 25 to your calendar (.ics) → With an account.
Among the 674 studies in Lymphoma, B-Cell, Marginal Zone with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research study will evaluate the safety and efficacy of a study drug called Umbralisib (also known as TGR-1202) alone as a possible treatment for Waldenstrom's Macroglobulinemia that has come back or that has not responded to standard treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with non-follicular indolent non-Hodgkin's lymphoma (iNHL) with MZL as the histology type received umbralisib, 800 milligrams (mg), orally, once daily (QD), until disease progression, unacceptable toxicity, or withdrawal from the study whichever occurred first.
Drug: Umbralisib
Participants with non-follicular iNHL with WM as the histology type received umbralisib, 800 mg, orally, QD, until disease progression, unacceptable toxicity, or withdrawal from the study whichever occurred first.
Drug: Umbralisib
Oral Daily Dose
Also known as: TGR-1202
Overall Response Rate (ORR) as Assessed by Revised Response Criteria for Non- Hodgkin's Lymphoma (Lugano Classification) and Consensus-Based 6th International Workshop on Waldenstrom's Macroglobulinemia (IWWM)
ORR for MZL=percentage of participants with complete response (CR)/partial response (PR). ORR for WM=CR/PR/very good partial response (VGPR)/minor response (MR). Response assessed per revised Lugano Classification for MZL \&per IWWM for WM participants. Per Lugano criteria CR=complete disappearance of all evidence of disease \& disease-related symptoms. PR=regression of measurable disease \& no new disease sites. Regression=≥50% decrease in the sum of the products of the diameters (SPD) of index lesions, with no increase in size of other lymph nodes/liver/spleen.Per IWWM criteria CR=disappearance of serum monoclonal immunoglobulin M (IgM) protein by immunofixation with a normal serum IgM level. VGPR=reduction of monoclonal IgM protein \>90% from baseline. PR=reduction of monoclonal IgM protein between 50-90% from baseline with regression of measurable disease. Regression defined in similar manner as Lugano Classification. MR=reduction of monoclonal IgM protein \>25% but \<50% from baseline.
Time frame: Every 3 cycles (1 Cycle = 28 days) from Day 1 Cycle 1 up to approximately 4.2 years
Duration of Response (DOR)
DOR is defined as the time from documentation of a response to treatment to the first documentation of tumor progression or death due to any cause, whichever comes first.
Time frame: From the first demonstration of response to umbralisib till disease progression/death (up to approximately 4.2 years)
Complete Response (CR) Rate
CR rate is defined as percentage of participants who achieved CR. CR was assessed using Revised Response Criteria for Non- Hodgkin's Lymphoma (Lugano Classification) for participants with MZL and Consensus-Based 6th IWWM for participants with WM. Per Lugano Classification, CR= the complete disappearance of all evidence of disease and disease-related symptoms i.e., liver/spleen non palpable and normal in size and disappearance of nodules related to lymphoma. Per IWWM criteria, CR=disappearance of serum monoclonal IgM protein by immunofixation with a normal serum IgM level, liver/spleen non palpable and normal in size and disappearance of nodes related to WM.
Time frame: Every 3 cycles (1 Cycle = 28 days) from Day 1 Cycle 1 up to approximately 4.2 years
Progression-Free Survival (PFS)
PFS is defined as the interval from Cycle 1 (1 cycle = 28 days) Day 1 to the earlier of the first documentation of definitive disease progression or death from any cause. Assessment of progressive disease (PD) was based on Revised Response Criteria for non-Hodgkin's lymphoma, Lugano Classification for participants with MZL and consensus-based 6th IWWM for participants with WM. Per Lugano Classification, PD was defined as the appearance of any new lesion more than 1.5 centimeters (cm) in any axis, even if other lesions are decreasing in size. At least a 50% increase from nadir in one of the following: SPD of index lesions, greatest transverse diameter (GTD) of any individual previously involved node, or GTD of any previously involved node provided that the GTD of that node is now ≥ 1.5 cm. Per IWWM criteria participants, PD was defined as more than 25% increase in serum IgM level from lowest nadir and/or progression in clinical features attributable to the disease.
Time frame: From date of randomization until the date of first documented progression (up to approximately 4.2 years)
Time to Treatment Failure (TTF)
TTF is defined as a composite endpoint measuring time from Cycle 1/Day 1 to discontinuation of treatment for any reason, including disease progression, treatment toxicity, and death. PD was assessed based on Revised Response Criteria for non-Hodgkin's lymphoma, Lugano Classification for participants with MZL and consensus-based 6th IWWM for participants with WM. Per Lugano Classification, PD was defined as the appearance of any new lesion more than 1.5 cm in any axis, even if other lesions are decreasing in size. At least a 50% increase from nadir in one of the following: SPD of index lesions, GTD of any individual previously involved node, or GTD of any previously involved node provided that the GTD of that node is now ≥ 1.5 cm. Per IWWM criteria PD was defined as more than 25% increase in serum IgM level from lowest nadir and/or progression in clinical features attributable to the disease.
Time frame: From first dose on Day 1 of Cycle 1 (28 days = 1 cycle) up to discontinuation of treatment (up to approximately 4.2 years)
Number of Participants With at Least One Adverse Event (AE)
An AE is any untoward medical occurrence in a participant that does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: From first dose of study treatment up to end of study (up to approximately 4.2 years)
A total of 21 participants were enrolled at 4 investigative centers across the United States from 30 November 2017 to 15 February 2022.
| Milestone | Marginal Zone Lymphoma (MZL): Umbralisib | Waldenstrom's Macroglobulinemia (WM): Umbralisib |
|---|---|---|
| Started | 8 | 13 |
| Safety population | 8 | 13 |
| Modified intent-to-treat (mitt) | 8 | 10 |
| Completed | 0 | 0 |
| Not completed | 8 | 13 |
| Withdrew: Adverse event | 1 | 4 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Investigator decision | 2 | 2 |
| Withdrew: Sponsor discontinuation of the study | 2 | 1 |
| Withdrew: Withdrawal of subject consent | 1 | 0 |
| Withdrew: Reason not specified | 1 | 0 |
| Withdrew: Disease progression | 0 | 6 |
ORR for MZL=percentage of participants with complete response (CR)/partial response (PR). ORR for WM=CR/PR/very good partial response (VGPR)/minor response (MR). Response assessed per revised Lugano Classification for MZL \&per IWWM for WM participants. Per Lugano criteria CR=complete disappearance of all evidence of disease \& disease-related symptoms. PR=regression of measurable disease \& no new disease sites. Regression=≥50% decrease in the sum of the products of the diameters (SPD) of index lesions, with no increase in size of other lymph nodes/liver/spleen.Per IWWM criteria CR=disappearance of serum monoclonal immunoglobulin M (IgM) protein by immunofixation with a normal serum IgM level. VGPR=reduction of monoclonal IgM protein \>90% from baseline. PR=reduction of monoclonal IgM protein between 50-90% from baseline with regression of measurable disease. Regression defined in similar manner as Lugano Classification. MR=reduction of monoclonal IgM protein \>25% but \<50% from baseline.
| percentage of participants | MZL: Umbralisib | WM: Umbralisib |
|---|---|---|
| Overall Response Rate (ORR) as Assessed by Revised Response Criteria for Non- Hodgkin's Lymphoma (Lugano Classification) and Consensus-Based 6th International Workshop on Waldenstrom's Macroglobulinemia (IWWM) | 37.5 (8.5 to 75.5) | 30.0 (6.7 to 65.2) |
DOR is defined as the time from documentation of a response to treatment to the first documentation of tumor progression or death due to any cause, whichever comes first.
| months | MZL: Umbralisib | WM: Umbralisib |
|---|---|---|
| Duration of Response (DOR) | 21.2 (3 to 33) | 13 (5 to 14) |
CR rate is defined as percentage of participants who achieved CR. CR was assessed using Revised Response Criteria for Non- Hodgkin's Lymphoma (Lugano Classification) for participants with MZL and Consensus-Based 6th IWWM for participants with WM. Per Lugano Classification, CR= the complete disappearance of all evidence of disease and disease-related symptoms i.e., liver/spleen non palpable and normal in size and disappearance of nodules related to lymphoma. Per IWWM criteria, CR=disappearance of serum monoclonal IgM protein by immunofixation with a normal serum IgM level, liver/spleen non palpable and normal in size and disappearance of nodes related to WM.
| percentage of participants | MZL: Umbralisib | WM: Umbralisib |
|---|---|---|
| Complete Response (CR) Rate | 12.5 (0.3 to 52.7) | 0 (NA to NA) |
PFS is defined as the interval from Cycle 1 (1 cycle = 28 days) Day 1 to the earlier of the first documentation of definitive disease progression or death from any cause. Assessment of progressive disease (PD) was based on Revised Response Criteria for non-Hodgkin's lymphoma, Lugano Classification for participants with MZL and consensus-based 6th IWWM for participants with WM. Per Lugano Classification, PD was defined as the appearance of any new lesion more than 1.5 centimeters (cm) in any axis, even if other lesions are decreasing in size. At least a 50% increase from nadir in one of the following: SPD of index lesions, greatest transverse diameter (GTD) of any individual previously involved node, or GTD of any previously involved node provided that the GTD of that node is now ≥ 1.5 cm. Per IWWM criteria participants, PD was defined as more than 25% increase in serum IgM level from lowest nadir and/or progression in clinical features attributable to the disease.
| months | MZL: Umbralisib | WM: Umbralisib |
|---|---|---|
| Progression-Free Survival (PFS) | 47.1 (1.4 to 47.1) | 18.4 (2.1 to 35.0) |
TTF is defined as a composite endpoint measuring time from Cycle 1/Day 1 to discontinuation of treatment for any reason, including disease progression, treatment toxicity, and death. PD was assessed based on Revised Response Criteria for non-Hodgkin's lymphoma, Lugano Classification for participants with MZL and consensus-based 6th IWWM for participants with WM. Per Lugano Classification, PD was defined as the appearance of any new lesion more than 1.5 cm in any axis, even if other lesions are decreasing in size. At least a 50% increase from nadir in one of the following: SPD of index lesions, GTD of any individual previously involved node, or GTD of any previously involved node provided that the GTD of that node is now ≥ 1.5 cm. Per IWWM criteria PD was defined as more than 25% increase in serum IgM level from lowest nadir and/or progression in clinical features attributable to the disease.
| months | MZL: Umbralisib | WM: Umbralisib |
|---|---|---|
| Time to Treatment Failure (TTF) | 13.1 (1.4 to NA) | 6.5 (2.1 to 15.9) |
An AE is any untoward medical occurrence in a participant that does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product.
| Participants | MZL: Umbralisib | WM: Umbralisib |
|---|---|---|
| Number of Participants With at Least One Adverse Event (AE) | 8 | 13 |
Collected over From first dose of study treatment up to end of study (up to approximately 4.2 years). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MZL: Umbralisib | 1/8 (12.5%) | 1/8 (12.5%) | 8/8 (100%) |
| WM: Umbralisib | 0/13 (0%) | 0/13 (0%) | 13/13 (100%) |
| Event | MZL: Umbralisib | WM: Umbralisib |
|---|---|---|
| ColitisGastrointestinal disorders | 1/8 | 0/13 |
| Event | MZL: Umbralisib | WM: Umbralisib |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 4/8 | 10/13 |
| NauseaGastrointestinal disorders | 4/8 | 7/13 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/8 | 5/13 |
| DizzinessNervous system disorders | 3/8 | 4/13 |
| AnaemiaBlood and lymphatic system disorders | 2/8 | 4/13 |
| Alanine aminotransferase increasedInvestigations | 2/8 | 4/13 |
| Aspartate aminotransferase increasedInvestigations | 2/8 | 4/13 |
| Abdominal distensionGastrointestinal disorders | 2/8 | 3/13 |
| Abdominal painGastrointestinal disorders | 2/8 | 1/13 |
| FatigueGeneral disorders | 2/8 | 3/13 |
Safety population included all enrolled participants who received at least one dose of study treatment.
| Age, Continuous(years) | MZL: Umbralisib | WM: Umbralisib | Total |
|---|---|---|---|
| Mean | 71.9 ± 7.64 | 67.7 ± 5.78 | 69.3 ± 6.69 |
| Sex: Female, Male(Participants) | MZL: Umbralisib | WM: Umbralisib | Total |
|---|---|---|---|
| Female | 4 | 6 | 10 |
| Male | 4 | 7 | 11 |
| Race/Ethnicity, Customized(Participants) | MZL: Umbralisib | WM: Umbralisib | Total |
|---|---|---|---|
| White | 6 | 11 | 17 |
| Black or African American | 1 | 1 | 2 |
| Asian | 1 | 0 | 1 |
| Other | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2017 to primary completion in Feb 2022, 50 months.
Results were first posted in Jun 2023, 1 year 4 months after primary completion.
Of 113 phase 2 interventional studies under Lymphoma, B-Cell, Marginal Zone, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 110. This study's 50 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Umbralisib
Lymphoma, B-Cell, Marginal Zone →